What alternative medications are similar to Auvelity (dextromethorphan + bupropion) for treating major depressive disorder?

Medications Similar to Auvelity for Major Depressive Disorder

For patients seeking alternatives to Auvelity, the most evidence-supported options include standard second-generation antidepressants (SSRIs, SNRIs like duloxetine, or bupropion monotherapy at higher doses), with novel alternatives including esketamine for treatment-resistant cases, or atypical antidepressants like mirtazapine, vortioxetine, or vilazodone depending on specific symptom profiles. 1, 2

Understanding Auvelity's Unique Profile

Auvelity combines dextromethorphan 45 mg with bupropion 105 mg twice daily. This represents a pharmacokinetic and pharmacodynamic synergy where:

• Dextromethorphan acts as an NMDA receptor antagonist and sigma-1 receptor agonist
• Bupropion inhibits CYP2D6, preventing rapid metabolism of dextromethorphan while adding norepinephrine/dopamine reuptake inhibition
• The combination shows faster onset (improvement by week 1) compared to traditional antidepressants 3, 4, 5

First-Line Alternative Options

Standard Second-Generation Antidepressants

SSRIs and SNRIs remain the primary alternatives with similar overall efficacy to Auvelity, though with slower onset of action. 1 Recent guidelines indicate that most first-step treatments for MDD provide similar symptomatic benefits, though the certainty of evidence is low for many comparisons.

Key options include:

• Duloxetine (SNRI): Demonstrated strong efficacy and tolerability, though one study showed higher suicide attempt rates in adolescents compared to bupropion 6
• Bupropion monotherapy at 300-450 mg/day: The higher doses used in standard practice (versus the 210 mg/day in Auvelity) may provide comparable efficacy, though direct comparisons are lacking 4, 7

Atypical Antidepressants with Unique Mechanisms

Mirtazapine offers a distinct mechanism through alpha-2 adrenoceptor blockade, enhancing norepinephrine and serotonin release. It shows improvement within 1-2 weeks and has the unique property of reducing cortisol levels. Dose range: 15-45 mg daily. Primary caveat: significant sedation and weight gain 7

Vortioxetine combines serotonin transporter inhibition with multimodal receptor activity (5-HT1A agonism, 5-HT3/5-HT7 antagonism). Shows improvement at 2 weeks with full effect at 4-6 weeks. Dose: up to 20 mg daily. Advantage: reduced sexual side effects compared to SSRIs 7

Vilazodone functions as both an SSRI and 5-HT1A partial agonist, potentially offering faster onset and better tolerability. Improvement noted within 1 week at the therapeutic dose of 40 mg daily 7

Treatment-Resistant Depression Options

Esketamine (Spravato)

For patients who have failed multiple antidepressants, esketamine represents the closest mechanistic alternative to Auvelity's NMDA antagonism. 2 Administered intranasally in clinical settings, it provides rapid antidepressant effects through glutamatergic modulation.

Augmentation Strategies with Second-Generation Antipsychotics

When switching is not preferred, augmentation with cariprazine (1.5 mg daily), aripiprazole, brexpiprazole, or quetiapine added to existing antidepressants shows efficacy. 2, 4 Cariprazine offers the advantage of minimal weight gain at the optimal 1.5 mg dose, with akathisia being the primary side effect.

Novel Emerging Options

Zuranolone (approved for postpartum depression, studied in MDD) offers a 14-day oral treatment course with sustained effects through GABA-A receptor modulation. While not yet approved for general MDD, it represents a mechanistically novel approach 4

Gepirone (recently approved 2023) acts as a 5-HT1A partial agonist without the sexual dysfunction, weight gain, or sedation typical of SSRIs. Maximum dose: 20 mg daily 4

Clinical Decision Algorithm

Step 1: Assess prior treatment failures and side effect profile

• If no prior SSRI/SNRI trial → Start with duloxetine or escitalopram
• If SSRI/SNRI failed due to sexual dysfunction → Consider bupropion 300-450 mg, mirtazapine, or vortioxetine
• If need for rapid onset is critical → Consider esketamine (if treatment-resistant) or mirtazapine

Step 2: Evaluate specific symptom domains

• Prominent insomnia → Mirtazapine or trazodone
• Anhedonia/low energy → Bupropion monotherapy at higher doses
• Cognitive symptoms → Vortioxetine (has procognitive effects)

Step 3: For inadequate response after 4-6 weeks

• Switch to different class OR
• Augment with SGA (cariprazine 1.5 mg preferred for metabolic profile) 1, 2

Critical Caveats

Bupropion considerations: Maximum doses are 450 mg/day (immediate-release) or 400 mg/day (sustained-release) due to seizure risk. Contraindicated in seizure disorders, eating disorders, and with abrupt benzodiazepine/alcohol discontinuation 3, 7

Onset expectations: While Auvelity shows improvement by week 1, most alternatives require 2-4 weeks for initial response and 4-6 weeks for full effect 7, 8

Guideline consensus: The 2023 ACP guideline emphasizes that most first-step MDD treatments provide similar benefits, but clinicians should focus on options with the most reliable evidence and consider adverse event profiles 1. The certainty of evidence remains low for most head-to-head comparisons, making tolerability and patient-specific factors paramount in selection.